Table 3 HALLMARK pathways from MsigDB obtained using the web tool ShinyGO. The enrichment has been separately evaluated by considering predicted targets of the 11-miRNA signature (List AWPC) and of the 15-miRNA signature (List Derived from Comparison Benign vs Mesothelioma lesions)
List AWPC | |||
Functional Category | Enrichment FDR | Genes in list | Total genes |
MSigDB:HALLMARK ESTROGEN RESPONSE EARLY | 8.00E-10 | 168 | 197 |
MSigDB:HALLMARK MTORC1 SIGNALING | 8.00E-10 | 168 | 197 |
MSigDB:HALLMARK IL2 STAT5 SIGNALING | 3.00E-09 | 165 | 195 |
MSigDB:HALLMARK INFLAMMATORY RESPONSE | 8.17E-08 | 163 | 197 |
MSigDB:HALLMARK UV RESPONSE DN | 8.17E-08 | 121 | 141 |
MSigDB:HALLMARK APOPTOSIS | 1.14E-07 | 134 | 159 |
MSigDB:HALLMARK APICAL JUNCTION | 1.14E-07 | 160 | 194 |
MSigDB:HALLMARK ANDROGEN RESPONSE | 2.77E-07 | 86 | 97 |
MSigDB:HALLMARK PI3K AKT MTOR SIGNALING | 4.38E-07 | 91 | 104 |
MSigDB:HALLMARK P53 PATHWAY | 7.97E-07 | 159 | 196 |
MSigDB:HALLMARK HYPOXIA | 1.07E-06 | 157 | 194 |
MSigDB:HALLMARK PROTEIN SECRETION | 1.07E-06 | 84 | 96 |
MSigDB:HALLMARK MITOTIC SPINDLE | 2.00E-06 | 159 | 198 |
MSigDB:HALLMARK GLYCOLYSIS | 2.00E-06 | 159 | 198 |
MSigDB:HALLMARK IL6 JAK STAT3 SIGNALING | 3.65E-06 | 76 | 87 |
MSigDB:HALLMARK TNFA SIGNALING VIA NFKB | 8.82E-06 | 157 | 198 |
MSigDB:HALLMARK KRAS SIGNALING UP | 9.12E-06 | 154 | 194 |
MSigDB:HALLMARK UV RESPONSE UP | 2.07E-05 | 124 | 154 |
MSigDB:HALLMARK E2F TARGETS | 9.99E-05 | 152 | 196 |
MSigDB:HALLMARK DNA REPAIR | 1.58E-04 | 112 | 141 |
MSigDB:HALLMARK HEME METABOLISM | 2.76E-04 | 151 | 197 |
MSigDB:HALLMARK G2M CHECKPOINT | 3.81E-04 | 149 | 195 |
MSigDB:HALLMARK EPITHELIAL MESENCHYMAL TRANSITION | 8.43E-04 | 149 | 197 |
MSigDB:HALLMARK TGF BETA SIGNALING | 1.17E-03 | 46 | 54 |
MSigDB:HALLMARK KRAS SIGNALING DN | 1.23E-03 | 144 | 191 |
MSigDB:HALLMARK MYOGENESIS | 1.62E-03 | 149 | 199 |
MSigDB:HALLMARK COMPLEMENT | 1.76E-03 | 146 | 195 |
MSigDB:HALLMARK ESTROGEN RESPONSE LATE | 1.77E-03 | 148 | 198 |
MSigDB:HALLMARK UNFOLDED PROTEIN RESPONSE | 2.38E-03 | 85 | 109 |
MSigDB:HALLMARK CHOLESTEROL HOMEOSTASIS | 2.60E-03 | 59 | 73 |
List Derived from Comparison Benign vs Mesothelioma lesions | |||
Functional Category | Enrichment FDR | Genes in list | Total genes |
MSigDB:HALLMARK UV RESPONSE DN | 5.89E-11 | 128 | 141 |
MSigDB:HALLMARK IL2 STAT5 SIGNALING | 1.54E-10 | 169 | 195 |
MSigDB:HALLMARK KRAS SIGNALING UP | 4.73E-10 | 167 | 194 |
MSigDB:HALLMARK ESTROGEN RESPONSE EARLY | 1.61E-09 | 168 | 197 |
MSigDB:HALLMARK MTORC1 SIGNALING | 3.40E-08 | 165 | 197 |
MSigDB:HALLMARK ADIPOGENESIS | 6.19E-08 | 159 | 190 |
MSigDB:HALLMARK PI3K AKT MTOR SIGNALING | 3.23E-07 | 92 | 104 |
MSigDB:HALLMARK APICAL JUNCTION | 3.23E-07 | 160 | 194 |
MSigDB:HALLMARK INFLAMMATORY RESPONSE | 3.23E-07 | 162 | 197 |
MSigDB:HALLMARK HEME METABOLISM | 3.23E-07 | 162 | 197 |
MSigDB:HALLMARK ANDROGEN RESPONSE | 4.47E-07 | 86 | 97 |
MSigDB:HALLMARK PROTEIN SECRETION | 5.62E-07 | 85 | 96 |
MSigDB:HALLMARK APOPTOSIS | 1.38E-06 | 132 | 159 |
MSigDB:HALLMARK P53 PATHWAY | 1.74E-06 | 159 | 196 |
MSigDB:HALLMARK TNFA SIGNALING VIA NFKB | 2.41E-06 | 160 | 198 |
MSigDB:HALLMARK COMPLEMENT | 4.42E-06 | 157 | 195 |
MSigDB:HALLMARK HYPOXIA | 5.18E-06 | 156 | 194 |
MSigDB:HALLMARK EPITHELIAL MESENCHYMAL TRANSITION | 5.69E-06 | 158 | 197 |
MSigDB:HALLMARK MYOGENESIS | 1.66E-05 | 158 | 199 |
MSigDB:HALLMARK IL6 JAK STAT3 SIGNALING | 1.82E-05 | 75 | 87 |
MSigDB:HALLMARK UV RESPONSE UP | 1.82E-05 | 125 | 154 |
MSigDB:HALLMARK GLYCOLYSIS | 1.39E-04 | 154 | 198 |
MSigDB:HALLMARK KRAS SIGNALING DN | 1.39E-04 | 149 | 191 |
MSigDB:HALLMARK MITOTIC SPINDLE | 2.53E-04 | 153 | 198 |
MSigDB:HALLMARK ESTROGEN RESPONSE LATE | 4.51E-04 | 152 | 198 |
MSigDB:HALLMARK OXIDATIVE PHOSPHORYLATION | 5.38E-04 | 141 | 183 |
MSigDB:HALLMARK PEROXISOME | 7.41E-04 | 83 | 103 |
MSigDB:HALLMARK APICAL SURFACE | 9.05E-04 | 38 | 43 |
MSigDB:HALLMARK G2M CHECKPOINT | 1.16E-03 | 148 | 195 |
MSigDB:HALLMARK DNA REPAIR | 1.78E-03 | 109 | 141 |